Prolongation of allograft survival with Ling Zhi-8, a new immunosuppressive drug.
van der Hem
L G
LG
Department of Surgery, University Hospital St Radboud, Nijmegen, The Netherlands.
van der Vliet
J A
JA
Bocken
C F
CF
Kino
K
K
Hoitsma
A J
AJ
Tax
W J
WJ
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D001786:Blood Glucose / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000601:surgery*; D005656:Fungal Proteins / Q000627:therapeutic use*; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016381:Islets of Langerhans Transplantation / Q000276:immunology*; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D013601:T-Lymphocytes / Q000276:immunology; D014184:Transplantation, Homologous / Q000276:immunology
D000276:Adjuvants, Immunologic; D001786:Blood Glucose; D005656:Fungal Proteins; D007166:Immunosuppressive Agents; C061148:LZ-8 protein, Ganoderma lucidum